Abbott launches dual-chamber pacemaker with first U.S. implants
November 7, 2023
The first U.S. commercial cases have been completed with the Abbott (NYSE: ABT)+
Aveir dual-chamber leadless pacemaker technology.
The first U.S. commercial cases have been completed with the Abbott (NYSE: ABT)+
Aveir dual-chamber leadless pacemaker technology.
An advanced closed-loop anesthesia delivery system that monitors brain state to tailor propofol dose and achieve exactly the desired level of unconsciousness could reduce post-op side effects.